China Pharma Holdings, Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019; financial statements are unaudited and prepared under U.S. GAAP. The company manufactures and markets generic and branded pharmaceuticals and biochemical products, primarily in China.
Financial performance and position
| Metric | Q1 2019 | Q1 2018 / prior balance date |
|---|---|---|
| Revenue | $2.929 million | $3.616 million |
| Gross profit / margin | $657,000 / 22.4% | $1.054 million / 29.1% |
| Operating loss | $334,000 | $141,000 |
| Net loss | $418,000 | $293,000 |
| Loss per share, basic and diluted | $0.01 | $0.01 |
| Net cash provided by operating activities | $91,000 | $524,000 |
| Cash and cash equivalents | $961,000 | $1.187 million at Dec. 31, 2018 |
| Restricted cash | $977,000 | $1.274 million at Dec. 31, 2018 |
| Total liabilities | $14.624 million | $15.179 million at Dec. 31, 2018 |
Cost of revenue was $2.273 million, or 78% of sales, versus $2.562 million, or 71%, a year earlier. Operating expenses totaled $991,000, down from $1.194 million; R&D expense rose to $70,000 from $22,000. Interest expense was $87,000. Foreign-currency translation income of $836,000 lifted comprehensive income to $418,000 despite the net loss.
At March 31, 2019, net accounts receivable was $845,000, inventory $4.934 million, and total assets $45.241 million. Construction-loan debt was $6.556 million, including $2.086 million current; banker’s acceptance notes payable were $977,000 and were matched by restricted cash. The company reported $214,000 in operating lease liabilities following adoption of the lease standard.
Changes and management commentary
- Revenue fell 19%, primarily from market fluctuations. Anti-viral/infection and respiratory sales declined $490,000, mainly due to lower Cefaclor sales; Vitamin B6 contributed to the decrease in “Other” sales.
- Gross margin decreased 6.7 percentage points. Management attributed the decline to lower revenue and a higher fixed-cost burden relative to sales.
- Selling expenses declined to $479,000 from $678,000, which management linked to sales-practice adjustments and reduced staffing. G&A declined modestly; bad-debt expense increased to $13,000 from $2,000.
- Operating cash flow decreased to $91,000 from $524,000. Cash declined by $225,000 during the quarter; investing outflow was $74,000 and financing outflow was $268,000.
Outlook, risks, and other notable items
- No specific revenue or earnings guidance was provided. Management believes operating cash flow will cover working-capital needs and anticipated capital expenditures for the next 12 months, including consistency evaluations and formula acquisitions. It cautions that changed circumstances could require additional financing or reduced discretionary spending; future financing is not assured.
- Management cites tighter Chinese drug-registration and generic-drug consistency-evaluation requirements, clinical-trial costs, environmental compliance costs, and shortages of active pharmaceutical ingredients and intermediates as pressures. Approval delays are expected for pipeline products, and the company has terminated progress on certain products. Approximately $300,000 in formula-approval contract payments is due upon completion of specified phases.
- Cash held in China is considered indefinitely reinvested and is not expected to be available to the parent or shareholders. PRC currency conversion and remittance controls, statutory reserve rules, and political, regulatory, economic, and foreign-exchange risks may restrict transfers.
- Receivables are a significant collection risk: the allowance for doubtful accounts was $18.296 million against reported net trade receivables of $845,000. The filing’s aging table reports 94.9% of receivables over 720 days at March 31, 2019; management says extended payment periods are common in the PRC pharmaceutical market. Two customers represented 49.3% and 10.6% of receivables.
- Disclosure controls were not effective at quarter-end due to a material weakness involving insufficient personnel knowledgeable in U.S. GAAP financial reporting. Management nevertheless stated the presented financial statements were fairly stated in all material respects.
- The company adopted lease accounting on January 1, 2019, recording $236,055 in right-of-use assets and lease liabilities; management said adoption did not materially affect operating results or cash flows. No off-balance-sheet arrangements were reported.
Most important facts for investors to verify
- Receivable aging, collectibility, and the adequacy of the $18.3 million allowance, particularly given the reported concentration of balances over 720 days old.
- Whether operating cash generation can fund scheduled loan repayments, capital needs, and regulatory-compliance spending while cash is restricted by its location in China.
- Progress and timing of product approvals and consistency evaluations, including the potential impact on existing products and the pipeline.
- Remediation of the material weakness in internal control over financial reporting and improvement in disclosure controls.
- Exact product-category percentages: the filing’s narrative and tables contain inconsistent figures for the anti-viral/infection and respiratory share of sales; the filing text does not provide a clear reconciled value.